SecBot SecBot
144 ·Filed Jun 30, 2026

ROIV

Roivant Sciences Ltd.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001950047-26-006641
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Watch for actual execution on Form 4 and whether other insiders follow. The filing comes during a period of 5 insider sales totaling $8.7M in the last 30 days — confirming a moderate selling pattern but not a cluster needing bearish read.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
ROIV ▲ +3.14% at T+60d
NEUTRAL call +3.14% · α vs SPY +0.18% · entry $35.03 → $36.13
Entry = T+0 close
Jun 30, 2026
via day close
T+1d
+0.29%
call +0.29% · α +0.42%
$35.13
settled 4mo ago
T+5d
+3.65%
call +3.65% · α +3.39%
$36.31
settled 4mo ago
T+20d
-6.17%
call -6.17% · α -3.98%
$32.87
settled 3mo ago
T+60d
+3.14%
call +3.14% · α +0.18%
$36.13
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Director Keith S. Manchester filed a Form 144 notice of intent to sell 200,000 ROIV shares with an estimated aggregate value of approximately $7.09M. The shares were acquired as founder stock on 12/31/2015. At a $25.2B market cap, the sale represents about 0.028% of shares outstanding — small in proportion but notable as a director-level sell. The filing signals Manchester's intent to sell, though actual execution is not guaranteed.

Key Facts

  • Form 144 filed by director Keith S. Manchester for proposed sale of 200,000 shares
  • Estimated aggregate market value of ~$7.09M at the time of filing (based on filing data)
  • Shares acquired as founder stock on 12/31/2015
  • Represents ~0.028% of total shares at $25.2B market cap
  • This is an intent-to-sell notice; sale may not be executed

Financial Impact

Up to $7.09M in director-level selling, negligible relative to $25.2B market cap

insider holdingsshare supply

Risk Factors

  • Director sale could precede other insider selling or signal peaked sentiment internally
  • If the entire 200k shares hit the market, adds modest sell-side pressure

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006641
Document: 0001950047-26-006641-index.html0001950047-26-006641
Document: 0001950047-26-006641.txt0001950047-26-006641
23 reports for ROIV
Performance horizon
67% Hit rate @ T+20 4 of 6 directional calls Went positive at some point 6 of 8 best @ T+60▲ +28.81%Mar 28, 2026
Filters
Rows
Reports for ROIV — sortable, filterable
TypeNow
Oct 21, 2026
5d ago
8-K
BULLISH ★ 7/10
$36.80awaiting T+20—$36.05 (−2.04%)
Oct 5, 2026
21d ago
Insider Cluster
BEARISH ★ 4/10
$35.53awaiting T+20—$36.05 (−1.46%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 17, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$39.77 $33.53▼ −15.69%▼ −15.89%$36.05 (−9.35%)
Sep 1, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$34.18 $36.57▲ +6.99%▲ +7.32%$36.05 (+5.47%)
Aug 27, 2026
8w ago
Press Release
BULLISH ★ 8/10
$37.58 $36.13▼ −3.86%▼ −3.35%$36.05 (−4.07%)
Aug 27, 2026
8w ago
Press Release
BULLISH ★ 8/10
$37.58 $36.13▼ −3.86%▼ −3.35%$36.05 (−4.07%)
Aug 26, 2026
8w ago
Press Release
BULLISH ★ 6/10
$36.75 $38.99▲ +6.10%▲ +4.89%$36.05 (−1.90%)
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$35.12 $34.41▼ −2.02%▼ −2.62%$36.05 (+2.65%)
Showing 10 of 23

US Market Status

Market Closed — Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026